Opioid Resource Center
Latest News
Study questions reliability of maternal drug testing
“Cannabis and methadone were the significant factors leading to discordance with positive newborn meconium, which may reflect prior use earlier in...
News
Two emerging drugs exacerbating opioid crisis
On their own, para-fluorofentanyl and metonitazene can kill the user through respiratory depression, said Dr. Jordan Trecki.
From the Journals
Buprenorphine may curb opioid-induced respiratory depression
“I think this is an approach that works, and this study makes that clear,” said Dr. Geert Jan Groeneveld.
News
Orally dissolving buprenorphine tied to severe tooth decay, FDA warns
Since buprenorphine was approved, the FDA has identified 305 cases of dental problems associated with orally dissolving buprenorphine.
From the Journals
Opioid agonist therapy guards against self-harm, suicide
These results highlight the importance of a ‘transition’ period when stopping OAT, said study investigator Dr. Prianka Padmanathan.
From the Journals
Short-acting opioids needed for withdrawal in U.S. hospitals, say experts
The short-acting drugs can complement methadone and buprenorphine to help patients get faster relief and help patients stay in the hospital to...
News
U.S. overdose deaths hit an all-time high
Fentanyl and methamphetamine are contributing to rising numbers of fatalities, federal officials say.
Conference Coverage
Warn patients about illicit drugs doctored with fentanyl
Most patients with drug use disorders are testing positive for fentanyl at his center, said Dr. Edwin A. Salsitz, of Mount Sinai Beth Israel.
From the Journals
Good news, bad news for buprenorphine in opioid use disorder
The findings “underscore the need to pursue actions that expand access to buprenorphine-based OUD treatment,” said Dr. Beth Han and associates.
Feature
Opioid prescribing mapped: Alabama highest, New York lowest
The Medicare Part D opioid prescribing rate dropped in all 50 states from 2014 to 2019, but disparities remain.
From the Journals
Opioid overdoses tied to lasting cognitive impairment
One study in the review found that about 39% of people seeking buprenorphine treatment suffered from neurocognitive impairment.